Skip to main content
. Author manuscript; available in PMC: 2017 Apr 17.
Published in final edited form as: Leukemia. 2016 Oct 17;31(3):688–696. doi: 10.1038/leu.2016.284

Figure 2. DOCK2 expression is decreased by stable and inducible expression of shRNA directed against DOCK2, and suppression of DOCK2 results in decreased Rac1 and STAT5 activity.

Figure 2

(A) Stable expression of shRNA directed against DOCK2 results in decreased DOCK2 expression (C: anti-GFP shRNA; KD: anti-DOCK2 shRNA). (B) Inducible expression of shRNAs directed against DOCK2 results in decreased expression of DOCK2 in TF-1 and MV4;11 cell lines (NS: non-specific control shRNA; KD1 and KD2: two different shRNAs directed against DOCK2). (C) Stable knockdown of DOCK2 results in decreased Rac1 activity (as measured by Rac1-GTP binding) in HB11;19, Molm14 and MV4;11 cell lines. Positive and negative controls were provided in the kit. (D) The effect of DOCK2 KD on STAT5 phosphorylation. The assay was performed in triplicate, and a statistically significant decrease in STAT5 phosphorylation was seen in MV4;11 cells (P ≤ 0.05, *) but not K562 cells.